
Please try another search
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company’s lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn’s, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Napoleone Ferrara | 68 | 2014 | Member of Scientific Advisory Board |
Gabriele Marco Antonio Cerrone | 53 | 2014 | Founder & Executive Chairman |
Willy Jules Simon | 74 | 2015 | Independent Non-Executive Director |
Kevan Herold | - | 2016 | Member of Scientific Advisory Board |
Arun J. Sanyal | - | 2017 | Member of Scientific Advisory Board |
John Patrick Brancaccio | 77 | 2020 | Independent Non-Executive Director |
Ivor R. Elrifi | - | 2024 | CEO & Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review